share_log

啓明醫療-B：法證調查的主要發現及繼續暫停買賣

VENUS MEDTECH-B: KEY FINDINGS OF THE FORENSIC INVESTIGATION AND CONTINUED SUSPENSION OF TRADING

香港交易所 ·  Feb 25 05:06
Summary by Moomoo AI
啟明醫療-B（股份代號：2500）於2024年2月23日公布，經由特別委員會委聘的法證顧問德勤諮詢（香港）有限公司完成法證調查，揭露了與前執行董事訾先生及曾先生有關的未經授權交易。調查發現，於2019年12月至2023年11月期間，啟明醫療及其附屬公司涉及多筆未披露資金往來，包括向江蘇吳中及Hangzhou Kuntai提供的未經授權貸款及擔保。總計約人民幣1.85億元轉賬至訾先生、曾先生或其關聯實體，並有約人民幣1.9億元從他們轉賬回公司。特別委員會認為訾先生、曾先生及前首席財務官馬先生應對由此造成的損失負責。公司已採取行動，包括要求相關各方還款並索賠損失，並進行內部控制的檢討與加強。由於事件，公司股份自2023年11月23日起在香港聯合交易所有限公司暫停買賣，並將繼續暫停直至符合復牌指引。
啟明醫療-B（股份代號：2500）於2024年2月23日公布，經由特別委員會委聘的法證顧問德勤諮詢（香港）有限公司完成法證調查，揭露了與前執行董事訾先生及曾先生有關的未經授權交易。調查發現，於2019年12月至2023年11月期間，啟明醫療及其附屬公司涉及多筆未披露資金往來，包括向江蘇吳中及Hangzhou Kuntai提供的未經授權貸款及擔保。總計約人民幣1.85億元轉賬至訾先生、曾先生或其關聯實體，並有約人民幣1.9億元從他們轉賬回公司。特別委員會認為訾先生、曾先生及前首席財務官馬先生應對由此造成的損失負責。公司已採取行動，包括要求相關各方還款並索賠損失，並進行內部控制的檢討與加強。由於事件，公司股份自2023年11月23日起在香港聯合交易所有限公司暫停買賣，並將繼續暫停直至符合復牌指引。
Kai Ming Medical -B (Stock Code: 2500) announced on 23 February 2024 that it has completed a forensic investigation into the conduct of a forensic investigation by Tak Kin Consulting (Hong Kong) Limited, appointed by the Special Committee, which revealed unauthorised transactions in relation to former Executive Directors Mr Cheng and Mr Tsang. The investigation found that between December 2019 and November 2023, Kai Ming Medical and its subsidiaries were involved in a number of undisclosed funds, including unauthorized loans and guarantees to Jiangsu Wuzhong and Hangzhou Kuntai. A total of approximately RMB 1.85 million was transferred to Mr. Zeng, Mr. Zeng or their related entities, and approximately RMB1.9 million was transferred back to the company from them. The Special Committee considers that Mr Tsang, Mr Tsang...Show More
Kai Ming Medical -B (Stock Code: 2500) announced on 23 February 2024 that it has completed a forensic investigation into the conduct of a forensic investigation by Tak Kin Consulting (Hong Kong) Limited, appointed by the Special Committee, which revealed unauthorised transactions in relation to former Executive Directors Mr Cheng and Mr Tsang. The investigation found that between December 2019 and November 2023, Kai Ming Medical and its subsidiaries were involved in a number of undisclosed funds, including unauthorized loans and guarantees to Jiangsu Wuzhong and Hangzhou Kuntai. A total of approximately RMB 1.85 million was transferred to Mr. Zeng, Mr. Zeng or their related entities, and approximately RMB1.9 million was transferred back to the company from them. The Special Committee considers that Mr Tsang, Mr Tsang and Mr Ma, the former Chief Financial Officer, are liable for the resulting losses. The company has taken action, including asking stakeholders to repay and claim losses, and to review and strengthen internal controls. Due to the incident, the Company's shares have been suspended from 23 November 2023 on the Stock Exchange of Hong Kong Limited and will continue to be suspended until compliance with the Replication Guidelines.

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more